Translational Research

The Kühn Lab are currently working to characterize cardiomyocyte proliferation in children and adults with heart failure.

Stimulating cardiomyocyte proliferation with periostin peptide or with neuregulin 1 shows great potential for repairing the mammalian heart after injury due to myocardial infarction, or to repair congenital heart defects, such as hypoplastic left heart syndrome.

As a step toward this goal, researchers in the Kühn Lab are currently working to characterize cardiomyocyte proliferation in children and adults with heart failure.

We have demonstrated that cardiomyocyte proliferation contributes to heart growth in babies and children. This raises the possibility to target this process with new regenerative therapies. One of our regeneration factors, neuregulin, is currently in clinical phase 2 testing in adult heart failure patients. We do not have financial interests in the development of neuregulin as a therapy and look forward to advancing toward clinical trials in children. The significance and promise of research on cardiomyocyte regeneration for developing new heart failure therapies for babies and infants was recognized by a working group of the National Heart Lung and Blood Institute in 2013.